


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings of claims in the application:

**Listing of Claims:**

1-48 (canceled)

49.(currently amended) A compound having the formula



wherein X is O; Y is O; m, n, p and q are each 0;  $\underline{R^4}, \underline{R^5}, \underline{R^7}$  and  $\underline{R^9}$   $\underline{R_4}, \underline{R_5}, \underline{R_7}$  and  $\underline{R_9}$  are each H;  $\underline{R^8} \underline{R_8}$  is phosphono;  $\underline{R^6} \underline{R_6}$  is selected from OH, CO<sub>2</sub>H and CONH<sub>2</sub>; and  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$  and  $\underline{R_3}$  are independently selected from C<sub>6</sub> acyl groups and C<sub>10</sub> acyl groups;

and pharmaceutically acceptable salts thereof.

50.(currently amended) A compound according to claim 49, wherein at least one of  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$  and  $\underline{R_3}$  is a C<sub>6</sub> acyl group and at least one other of  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$  and  $\underline{R_3}$  is a C<sub>10</sub> acyl group.

51.(currently amended) A compound in accordance with claim 49, wherein two of  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$  and  $\underline{R_3}$  are C<sub>6</sub> acyl groups.

52.(currently amended) A compound in accordance with claim 49, wherein two of  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$ , and  $\underline{R_3}$  are C<sub>10</sub> acyl groups.

53.(currently amended) A compound in accordance with claim 49, wherein  $\underline{R^6} \underline{R_6}$  is CO<sub>2</sub>H.

54.(currently amended) A compound in accordance with claim 53, wherein  $\underline{R^1} \underline{R_1}$  is a C<sub>6</sub> acyl group and  $\underline{R^2}$  and  $\underline{R^3} \underline{R_2}$  and  $\underline{R_3}$  are both C<sub>10</sub> acyl groups.

55.(currently amended) A compound in accordance with claim 53, wherein  $\underline{R^3} \underline{R_3}$  is a C<sub>10</sub> acyl group and  $\underline{R^1}$  and  $\underline{R^2} \underline{R_1}$  and  $\underline{R_2}$  are both C<sub>6</sub> acyl groups.

56.(currently amended) A compound in accordance with claim 53, wherein  $\underline{R^1}$  is a C<sub>10</sub> acyl group and  $\underline{R^2}$  and  $\underline{R^3} \underline{R_2}$  and  $\underline{R_3}$  are both C<sub>6</sub> acyl groups.

57.(currently amended) A compound in accordance with claim 53, wherein  $\underline{R^1}, \underline{R^2}$  and  $\underline{R^3} \underline{R_1}, \underline{R_2}$  and  $\underline{R_3}$  are all C<sub>6</sub> acyl groups.

59 58.(currently amended) A pharmaceutically acceptable ~~salt~~ salt in accordance with claim 49.

Appl. No. 10/043,086  
Amdt. dated April 18, 2005  
Reply to Office Action of March 14, 2005

PATENT

60 59.(currently amended) A pharmaceutically acceptable salt in accordance with claim 60 50.

61 60.(currently amended) A pharmaceutical composition comprising a compound of claim 49 and a pharmaceutically acceptable carrier.

62 61.(currently amended) A method for enhancing the immune response of a mammal comprising administering to the mammal an effective amount of a compound of claim 49.